Cingulate rises after positive late-stage data on ADHD drug

Cingulate

11/07/2023 13:39

** Shares of biotech co Cingulate  CING.O  rise 29% to $1.19
premarket
    ** Co reports positive late-stage data on its experimental
lead drug, CTx-1301, evaluating it as a treatment for attention
deficit-hyperactivity disorder (ADHD) in adults 
    ** CTx-1301 showed a meaningful trend of improvement of ADHD
symptoms in adults - co
    ** CING plans to initiate its late-stage trial of testing a
fixed-dose of the drug in pediatric and adolescent patients this
month 
    ** To file its application in U.S. seeking marketing
authorization for the drug by mid-2024 
    ** As of last close, CING down ~8% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))